These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 24607445)

  • 1. Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: focus on modulation of CNS monoamine neurotransmitter release.
    Finberg JP
    Pharmacol Ther; 2014 Aug; 143(2):133-52. PubMed ID: 24607445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation.
    Youdim MB; Weinstock M
    Neurotoxicology; 2004 Jan; 25(1-2):243-50. PubMed ID: 14697899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Monoamine oxidase as a target for drug action].
    Drozak J; Kozłowski M
    Postepy Hig Med Dosw (Online); 2006; 60():498-515. PubMed ID: 17060892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
    Youdim MB; Fridkin M; Zheng H
    Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopamine metabolism and neurotransmission in primate brain in relationship to monoamine oxidase A and B inhibition.
    Youdim MB; Riederer P
    J Neural Transm Gen Sect; 1993; 91(2-3):181-95. PubMed ID: 8390270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion.
    Gal S; Zheng H; Fridkin M; Youdim MB
    J Neurochem; 2005 Oct; 95(1):79-88. PubMed ID: 16181414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antidepressant-like effect of the novel MAO inhibitor 2-(3,4-dimethoxy-phenyl)-4,5-dihydro-1H-imidazole (2-DMPI) in mice.
    Villarinho JG; Fachinetto R; de Vargas Pinheiro F; da Silva Sant'Anna G; Machado P; Dombrowski PA; da Cunha C; de Almeida Cabrini D; Pinto Martins MA; Gauze Bonacorso H; Zanatta N; Antonello Rubin M; Ferreira J
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Oct; 39(1):31-9. PubMed ID: 22525823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Inhibitory monoamine oxidases of the new generation].
    Nowakowska E; Chodera A
    Pol Merkur Lekarski; 1997 Jul; 3(13):1-4. PubMed ID: 9432289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychotropic drugs (2). Interaction between monoamine oxidase (MAO) inhibitors and other substances.
    Sjöqvist F
    Proc R Soc Med; 1965 Nov; 58(11 Part 2):967-78. PubMed ID: 4952963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroprotective and neurorestorative activities of a novel iron chelator-brain selective monoamine oxidase-A/monoamine oxidase-B inhibitor in animal models of Parkinson's disease and aging.
    Bar-Am O; Amit T; Kupershmidt L; Aluf Y; Mechlovich D; Kabha H; Danovitch L; Zurawski VR; Youdim MB; Weinreb O
    Neurobiol Aging; 2015 Mar; 36(3):1529-42. PubMed ID: 25499799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
    Guay DR
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition.
    Zheng H; Gal S; Weiner LM; Bar-Am O; Warshawsky A; Fridkin M; Youdim MB
    J Neurochem; 2005 Oct; 95(1):68-78. PubMed ID: 16181413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of co-administration of varenicline and antidepressants on extracellular monoamine concentrations in rat prefrontal cortex.
    Rollema H; Wilson GG; Lee TC; Folgering JH; Flik G
    Neurochem Int; 2011 Jan; 58(1):78-84. PubMed ID: 21056607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and early clinical evaluation of selective inhibitors of monoamine oxidase.
    Palfreyman MG; McDonald IA; Bey P; Schechter PJ; Sjoerdsma A
    Prog Neuropsychopharmacol Biol Psychiatry; 1988; 12(6):967-87. PubMed ID: 3266532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of lamotrigine on the activities of monoamine oxidases A and B in vitro and on monoamine disposition in vivo.
    Southam E; Pereira R; Stratton SC; Sargent R; Ford AJ; Butterfield LJ; Wheable JD; Beckett SR; Roe C; Marsden CA; Hagan RM
    Eur J Pharmacol; 2005 Sep; 519(3):237-45. PubMed ID: 16129425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of co-administration of subchronic lithium pretreatment and acute MAO inhibitors on extracellular monoamine levels and the expression of contextual conditioned fear in rats.
    Kitaichi Y; Inoue T; Nakagawa S; Izumi T; Koyama T
    Eur J Pharmacol; 2006 Feb; 532(3):236-45. PubMed ID: 16487506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroprotective profile of the multitarget drug rasagiline in Parkinson's disease.
    Weinreb O; Amit T; Riederer P; Youdim MB; Mandel SA
    Int Rev Neurobiol; 2011; 100():127-49. PubMed ID: 21971006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined treatment with MAO-A inhibitor and MAO-B inhibitor increases extracellular noradrenaline levels more than MAO-A inhibitor alone through increases in beta-phenylethylamine.
    Kitaichi Y; Inoue T; Nakagawa S; Boku S; Izumi T; Koyama T
    Eur J Pharmacol; 2010 Jul; 637(1-3):77-82. PubMed ID: 20406628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson's disease.
    Szökő É; Tábi T; Riederer P; Vécsei L; Magyar K
    J Neural Transm (Vienna); 2018 Nov; 125(11):1735-1749. PubMed ID: 29417334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.